Effectiveness of omeprazole for the treatment of upper gastrointestinal lesions in rheumatoid arthritis patients

References

• Langman MJS. Epidemiologic evidence on the association between peptic ulcerations and anti-inflammatory drug use. Gastroenterology 1989;96:640–6.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Nobunaga T, Saitoh T, Asaki S, Ogawa N. Epidemi-ology study on upper gastrointestinal lesions by non steroidal anti-inflammatory drugs (in Japanese). Ryumachi 1991;31:96–111.
   Google Scholar
• Ament PW, Childers RS. Prophylaxis and treatment of NSAID-induced gastropathy. Am Fam Physician 1997;55:1323–32.
   PubMedGoogle Scholar
• Bank S, Greenberg RE, Magier D, Lavin PT. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Clin Ther 1991;13:304–18.
   PubMedGoogle Scholar
• Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991:32:252–5.
   Google Scholar
• O'Laughlin JC, Silvoso GK, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspi-rin. A double-blind study with cimetidine and follow-up. Dig Dis Sci 1982;27:976–80.
   Google Scholar
• Bamberg P, Caswell CM, Frame MH, Lam SK, Wong EC. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol 1992;7: 577–85.
   Google Scholar
• Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69–75.
   PubMed Web of Science ®Google Scholar
• Chelvam P, Wong ECK. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists. J Gastroenterol Hepatol 1989;4\(suppl 2):75–81.
   Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719–26.
   Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727–34.
   PubMed Web of Science ®Google Scholar
• Brunner GHG, Lamberts R, Creutzfeldt W. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990;47\(suppl 1): 64–8.
   Google Scholar
• Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lans-oprazole Maintenance Study Group. Am J Gastroenterol 1996;91: 1758–65.
   PubMedGoogle Scholar
• Gladziwa U, Klotz U. Pharmacokinetic optimisation of the treat-ment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994;27:393–408.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxico-logical studies on omeprazole. Scand J Gastroenterol 1985; 20\(suppl 108):53–69.
   Google Scholar
• Sakita T, Hukutomi H, Oguro H, Tagasu Y, Miwa T, Inui S, et al. Diagnosis of gastric ulcer. In: Yoshitoshi Y, editor. All about gas-tric and duodenal ulcer. Tokyo: Nankodo; 1972. p. 200–11.
   Google Scholar
• Matsukawa Y, Tomita Y, Nishinarita S, Hone T, Kato K, Arakawa Y, et al. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing. J Int Med Res 1997;25:190–5.
   PubMed Web of Science ®Google Scholar
• Soll AH. Consensus conference. Medical treatment of peptic ulcer disease: practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996;275:622–9.
   Google Scholar
• Larsson H, Carlsson E, Mattson H, Lundell L, Sundler G, Wallmark B, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391–9.
   Google Scholar
• Hakanson R, Sundler F. Histamine-producing cells in the stomach and their role in the regulation of acid secretion. Scand J Gastroenterol Suppl 1991;180:88–94.
   PubMedGoogle Scholar
• Lambers R, Creutzfeldt W, StOckmann F, Jacubaschke U, Mass S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988;39:126–35.
   PubMedGoogle Scholar
• Maton PN, Vinayek R, Frucht H, MacArther KA, Miller LS, Saeed ZA, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroen-terology 1989;97:827–36.
   PubMed Web of Science ®Google Scholar
• Okano N. Clinical assessment of progression rate of gastric ulcer scar from red scar stage (Stage 51) to white scar stage (Stage S2) and maintenance treatment (in Japanese with English abstract). J Nihon Univ Med Assoc 1992;51:492–8.
   Google Scholar
• Tanaka M, Maruoka A, Chijiiwa Y, Tanaka M, Nawata H. Endo-scopic ultrasonographic evaluation of gastric ulcer healing on treat-ment with proton pump inhibitors versus H2-receptor antagonists. Scand J Gastroenterol 1994;29: 1140–4.
   Google Scholar
• Howden CW, Payton CD, Meredith PA, Hughes DMA, Macdougall Al, Reid JL, et al. Antisecretory effect and oral phar-macokinetics of omeprazole in patients with chronic renal failure. Eur J Chin Pharmacol 1985;28:637–40.
   PubMedGoogle Scholar
• Baba S, Masago A, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 y: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995;4:1083–7.
   PubMed Web of Science ®Google Scholar
• Porro GB, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol 1997;92:663–7.
   Google Scholar
• Agrawal NM, Van Kerckhove HE, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for prevention of gas-troduodenal ulcers. A one-year study. Dig Dis Sci 1995;40:1125-31. and nonsteroidal antiinflammatory drugs. Am J Gastroenterol 1992;87: 1732–5.
   Google Scholar
• Goggin PM, Collins DA, Jazrawi RP, Jackson PA, Corbishley CM, Bourke BE, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug 33. induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993;34:1677–80.
   Google Scholar
• Henriksson K, Uribe A, Sandstedt B, Nord CE. Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gas- 34. troduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1993;38:1688–96.
   Google Scholar
• Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine,
   Google Scholar
• Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid systhesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748–51.
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cycloxygenase 2 inhibitor. Arthritis Rheum 1998;41:1591–602.
   PubMed Web of Science ®Google Scholar